Moderna and Merck melanoma vaccine clinical trial data released early

Data evaluating an experimental personalized mRNA cancer vaccine developed by Moderna and Merck was released early at the European Society for Medical Oncology conference in Madrid, STAT News reported. The trial results leaked at the start of the annual medical meeting. [1][2]

According to STAT News, the clinical trial data showed that the combination treatment reduced recurrence-free survival and delayed the time until distant metastasis occurred in patients. The personalized vaccine is designed to target melanoma after initial treatment. [1][2]

As FTMQ Health reported earlier, pharmaceutical companies Merck and Moderna have been pairing personalized mRNA vaccines with the immunotherapy drug Keytruda to target skin cancer tumors. The ongoing clinical trial focuses on patients diagnosed with high-risk melanoma following the surgical removal of their tumors. [5]

Vaccines function by stimulating the immune system to recognize and destroy specific disease-causing agents or malignant cells. Medical researchers continue to track trial participants at the conference in Madrid to evaluate long-term outcomes and detailed patient responses. [1][4]